Home » Stocks » ADYX

Adynxx, Inc. (ADYX)

Stock Price: $0.2530 USD -0.1870 (-42.50%)
Updated Feb 25, 2021 9:30 AM EST - Market closed
Market Cap 1.47M
Revenue (ttm) 589,000
Net Income (ttm) -8.73M
Shares Out 5.81M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $0.2530
Previous Close $0.4400
Change ($) -0.1870
Change (%) -42.50%
Day's Open 0.2530
Day's Range 0.2530 - 0.2530
Day's Volume 1,189
52-Week Range 0.0455 - 1.18

News

There are no news available yet.

About ADYX

Adynxx, a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Industry
Biotechnology
Founded
2007
CEO
David Johnson
Employees
6
Stock Exchange
OTCMKTS
Ticker Symbol
ADYX
Full Company Profile

Financial Performance

In 2018, Adynxx's revenue was $2.22 million, an increase of 9.76% compared to the previous year's $2.02 million. Losses were -$8.42 million, -67.26% less than in 2017.

Financial Statements